poisar

Stocks · News reference

Grifols Announces Completion Of Follow-Up For All 345 Patients In Phase 3 SPARTA Trial Of Prolastin-C In Alpha-1 Emphysema; Topline Data Expected By End Of 2026

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

GRFS
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Researchandmarkets.Com

    European Human Biospecimen Market Forecasts Growth from $881.8M (2025) to $1.94B by 2035, Profiling Grifols, Logical Biological & Europa Biosite

    The European human biospecimen market is projected to grow at an 8.24% CAGR from $881.8 million in 2025 to $1.94 billion by 2035, driven by increasing demand for precision medicine, oncology research, and expanding biobanks. Growth is supported by rising pharmaceutical R&D spending and EU-funded initiatives, though challenges include stringent GDPR regulations, high operational costs, and variability in consent frameworks across countries.

    GRFS
  2. Sns Insider

    Intravenous Immunoglobulin Market Size Worth USD 30.83 Billion by 2035, Growing at 7.49% CAGR – SNS Insider

    The global intravenous immunoglobulin (IVIG) market is projected to grow from USD 14.98 billion in 2025 to USD 30.83 billion by 2035, at a CAGR of 7.49%. Growth is driven by expanding neurological indications, increased plasma collection capacity, and rising demand for immunoglobulin-based treatments. However, plasma supply dependency and a 100% U.S. tariff on imported IVIG products implemented in October 2025 pose significant constraints. North America leads the market, while Asia-Pacific shows the fastest growth.

    CSLLYGRFSBAXEBSTAK
  3. Healthcare Foresights

    [Latest] Global Botulinum Toxin in Urology Market Size/Share Worth USD 1.98 Billion by 2035 at a 6.08% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

    The global botulinum toxin in urology market is projected to grow from USD 1.1 billion in 2025 to USD 1.98 billion by 2035, at a CAGR of 6.08%. Growth is driven by increasing prevalence of urological disorders, aging populations, preference for minimally invasive treatments, and advancements in injection techniques. OnabotulinumtoxinA (Botox) leads the market, with overactive bladder being the largest application segment.

    CSLLYGRFSTAK